Adagene (FRA:978) Short Interest


FRA:978 Adagene Inc FRA:978
42 GF Score
Price €3.32
GF Value €11.04
! 5 Warning Signs
View Full Analysis

What is Adagene Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:978 vs CNTX, TARA, NVCT: Short Interest Comparison

For the Biotechnology subindustry, Adagene's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adagene Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adagene's Short Interest distribution charts can be found below:

* The bar in red indicates where Adagene's Short Interest falls into.


FRA:978
42GF Score
Adagene Inc FRA:978
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Adagene (FRA:978) Overvalued in 2026?

Based on GuruFocus' analysis, Adagene stock appears to be undervalued. The current stock price of €3.32 is trading 69.9% below its estimated GF Value™ of €11.04.

Key valuation signals for FRA:978:

  • Short Interest:
  • GF Value™: €11.04 vs. price of €3.32 (69.9% below fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adagene Business Description

Other Exchanges ADAG:USA
Address Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score

Get the complete analysis for FRA:978

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.32
Price
€11.04
GF Value